Management and Outcome of Patients Admitted With Tricuspid Regurgitation in France

Can J Cardiol. 2021 Jul;37(7):1078-1085. doi: 10.1016/j.cjca.2020.12.012. Epub 2020 Dec 25.

Abstract

Background: Growing evidence shows a major outcome impact and undertreatment of tricuspid regurgitation (TR), but large and comprehensive contemporary reports of management and outcome at the nationwide level are lacking.

Methods: We gathered all consecutive patients admitted with a diagnosis of likely functional TR in 2014-2015 in France from the Programme de Médicalisation des Systèmes d'Information national database and collected rate of surgery, in-hospital mortality, 1-year mortality, or heart failure (HF) readmission rates.

Results: In 2014-2015, 17,676 consecutive patients (75 ± 14 years of age, 51% female) were admitted with a TR diagnosis. Charlson index was ≥ 2 in 56% of the population and 46% presented with HF. TR was associated with prior cardiac surgery, ischemic/dilated cardiomyopathy, or mitral regurgitation in 73% of patients. Only 10% of TR patients overall and 67% of those undergoing mitral valve surgery received a tricuspid valve intervention. Among the 13,654 (77%) conservatively managed patients, in-hospital mortality, 1-year mortality, and 1-year mortality or HF readmission rates were 5.1%, 17.8%, and 41%, respectively, overall, and 5.3%,17.2%, and 37%, respectively, among those with no underlying medical conditions (8-fold higher than predicted for age and gender).

Conclusions: This nationwide cohort of patients admitted with TR included elderly patients with frequent comorbidities/underlying cardiac diseases. In patients conservatively managed, mortality and morbidity were considerably high over a short time span. Despite this poor prognosis, only 10% of patients underwent a tricuspid valve intervention. These nationwide data showing a considerable risk and potential underuse of treatment highlight the critical need to develop strategies to improve the management and outcomes of TR patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiomyopathies* / epidemiology
  • Cardiomyopathies* / etiology
  • Cardiomyopathies* / therapy
  • Female
  • France / epidemiology
  • Health Services Misuse / prevention & control
  • Heart Failure / epidemiology
  • Heart Failure / etiology
  • Heart Failure / therapy
  • Heart Valve Diseases* / complications
  • Heart Valve Diseases* / epidemiology
  • Heart Valve Diseases* / surgery
  • Heart Valve Prosthesis Implantation / adverse effects*
  • Heart Valve Prosthesis Implantation / methods
  • Heart Valve Prosthesis Implantation / statistics & numerical data
  • Hospital Mortality
  • Hospitalization / statistics & numerical data
  • Humans
  • Long Term Adverse Effects / mortality
  • Long Term Adverse Effects / therapy
  • Male
  • Outcome and Process Assessment, Health Care
  • Patient Readmission / statistics & numerical data
  • Prognosis
  • Quality Improvement
  • Tricuspid Valve / surgery
  • Tricuspid Valve Insufficiency* / etiology
  • Tricuspid Valve Insufficiency* / mortality
  • Tricuspid Valve Insufficiency* / physiopathology
  • Tricuspid Valve Insufficiency* / therapy